These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 9128853

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. AM630 antagonism of cannabinoid-stimulated [35S]GTP gamma S binding in the mouse brain.
    Hosohata Y, Quock RM, Hosohata K, Makriyannis A, Consroe P, Roeske WR, Yamamura HI.
    Eur J Pharmacol; 1997 Feb 19; 321(1):R1-3. PubMed ID: 9083796
    [Abstract] [Full Text] [Related]

  • 3. Effect of chronic administration of R-(+)-[2,3-Dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate (WIN55,212-2) or delta(9)-tetrahydrocannabinol on cannabinoid receptor adaptation in mice.
    Sim-Selley LJ, Martin BR.
    J Pharmacol Exp Ther; 2002 Oct 19; 303(1):36-44. PubMed ID: 12235230
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Cannabinoid receptor stimulation of guanosine-5'-O-(3-[35S]thio)triphosphate binding in rat brain membranes.
    Selley DE, Stark S, Sim LJ, Childers SR.
    Life Sci; 1996 Oct 19; 59(8):659-68. PubMed ID: 8761016
    [Abstract] [Full Text] [Related]

  • 7. Antiemetic and motor-depressive actions of CP55,940: cannabinoid CB1 receptor characterization, distribution, and G-protein activation.
    Darmani NA, Sim-Selley LJ, Martin BR, Janoyan JJ, Crim JL, Parekh B, Breivogel CS.
    Eur J Pharmacol; 2003 Jan 10; 459(1):83-95. PubMed ID: 12505537
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Effects of chronic treatment with delta9-tetrahydrocannabinol on cannabinoid-stimulated [35S]GTPgammaS autoradiography in rat brain.
    Sim LJ, Hampson RE, Deadwyler SA, Childers SR.
    J Neurosci; 1996 Dec 15; 16(24):8057-66. PubMed ID: 8987831
    [Abstract] [Full Text] [Related]

  • 10. Interaction of brain cannabinoid receptors with guanine nucleotide binding protein: a radioligand binding study.
    Petitet F, Jeantaud B, Capet M, Doble A.
    Biochem Pharmacol; 1997 Dec 01; 54(11):1267-70. PubMed ID: 9416978
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Inhibitory effects of SR141716A on G-protein activation in rat brain.
    Sim-Selley LJ, Brunk LK, Selley DE.
    Eur J Pharmacol; 2001 Mar 02; 414(2-3):135-43. PubMed ID: 11239913
    [Abstract] [Full Text] [Related]

  • 14. The psychoactive plant cannabinoid, Delta9-tetrahydrocannabinol, is antagonized by Delta8- and Delta9-tetrahydrocannabivarin in mice in vivo.
    Pertwee RG, Thomas A, Stevenson LA, Ross RA, Varvel SA, Lichtman AH, Martin BR, Razdan RK.
    Br J Pharmacol; 2007 Mar 02; 150(5):586-94. PubMed ID: 17245367
    [Abstract] [Full Text] [Related]

  • 15. SR141716A is an inverse agonist at the human cannabinoid CB1 receptor.
    Landsman RS, Burkey TH, Consroe P, Roeske WR, Yamamura HI.
    Eur J Pharmacol; 1997 Sep 03; 334(1):R1-2. PubMed ID: 9346339
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.